2009
DOI: 10.1055/s-0029-1220881
|View full text |Cite
|
Sign up to set email alerts
|

Diffuse Marrow Changes

Abstract: Magnetic resonance imaging (MRI) to date remains the only imaging modality allowing direct visualization of the bone marrow compartment, in general having high sensitivity for bone marrow abnormalities. However, signal intensity changes in many different diseases presented with diffuse bone marrow infiltration show more overlap than difference, resulting in poor specificity. Therefore, MRI cannot be applied for initial diagnostic purposes in most diseases but should be reserved for staging, monitoring of thera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2016
2016

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 63 publications
(95 reference statements)
0
1
0
Order By: Relevance
“…New drugs with antiangiogenic activity, such as bevacizumab that binds and inactivates vascular endothelial growth factor (VEGF) or VEGF-tyrosine kinase inhibitors seem promising. New macromolecular contrast medium (MMCM) agents can most likely monitor this treatment response in patients (Berger et al 2009 ), although larger patients cohorts have yet to be investigated. Thalidomide has been shown to possess antiangiogenic potential among other antitumoral effects and is being studied for the treatment of multiple myeloma in particular.…”
Section: Antiangiogenic Drugs and Microcirculationmentioning
confidence: 99%
“…New drugs with antiangiogenic activity, such as bevacizumab that binds and inactivates vascular endothelial growth factor (VEGF) or VEGF-tyrosine kinase inhibitors seem promising. New macromolecular contrast medium (MMCM) agents can most likely monitor this treatment response in patients (Berger et al 2009 ), although larger patients cohorts have yet to be investigated. Thalidomide has been shown to possess antiangiogenic potential among other antitumoral effects and is being studied for the treatment of multiple myeloma in particular.…”
Section: Antiangiogenic Drugs and Microcirculationmentioning
confidence: 99%